Novel POC Troponin Assay Rules Out Acute MI
By LabMedica International staff writers Posted on 05 Nov 2018 |
Image: The i-STAT cardiac troponin I assay; healthcare professionals can obtain quantitative measurement of cardiac troponin I (cTnI) in ten minutes without leaving the patient\'s side (Photo courtesy of Abbott Point of Care).
More than seven billion diagnostic tests are run in the USA each year to help physicians make accurate, timely decisions about a person's medical treatment. Emergency department (ED) investigations of patients with suspected acute myocardial infarction (AMI) are time consuming, partly because of the turnaround time of laboratory tests.
Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times. The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity laboratory tests.
A team of scientists collaborating with Christchurch Hospital (Christchurch, New Zealand) evaluated 354 adults, including 255 (72.0%) men; mean age, 62 ± 12 years, who entered an emergency department with symptoms of acute coronary syndrome, such as a heart attack. Troponin concentrations were measured on ED arrival with both a novel point-of-care assay i-STAT TnI-Nx and a high-sensitivity troponin I assay, the Architect hs-cTnI.
The investigators reported that of 354 patients, 57 (16.1%) experienced an AMI. Eighty-five patients (24.0%) presented to the ED less than three hours after symptom onset. No difference was found between the area under the curve (AUC) of the TnI-Nx assay (0.975) and the hs-cTnI assay (0.970). A TnI-Nx assay result of less than 11 ng/L identified 201 patients (56.7%) as low risk, with sensitivity and a negative predictive value of 100%. In comparison, an hs-cTnI assay result of less than 3 ng/L identified 154 patients (43.5%) as low risk, with a sensitivity and a negative predictive value of 100%.
The authors concluded that a novel point-of-care troponin assay that can produce a result 15 minutes after blood sampling had comparable discrimination ability to an hs-cTnI assay for ruling out AMI after a single blood test. Use in the ED may facilitate earlier decision-making and could expedite the safe discharge of a large proportion of low-risk patients. Additional usefulness of this assay is likely to be found outside of the ED, such as in rural hospitals and general practices where there is limited rapid access to laboratory-based troponin assays. The study was published on October 17, 2018, in the journal JAMA Cardiology.
Related Links:
Christchurch Hospital
Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times. The goal of with-patient diagnostic tests is to deliver results with accuracy similar to the gold standard of high-sensitivity laboratory tests.
A team of scientists collaborating with Christchurch Hospital (Christchurch, New Zealand) evaluated 354 adults, including 255 (72.0%) men; mean age, 62 ± 12 years, who entered an emergency department with symptoms of acute coronary syndrome, such as a heart attack. Troponin concentrations were measured on ED arrival with both a novel point-of-care assay i-STAT TnI-Nx and a high-sensitivity troponin I assay, the Architect hs-cTnI.
The investigators reported that of 354 patients, 57 (16.1%) experienced an AMI. Eighty-five patients (24.0%) presented to the ED less than three hours after symptom onset. No difference was found between the area under the curve (AUC) of the TnI-Nx assay (0.975) and the hs-cTnI assay (0.970). A TnI-Nx assay result of less than 11 ng/L identified 201 patients (56.7%) as low risk, with sensitivity and a negative predictive value of 100%. In comparison, an hs-cTnI assay result of less than 3 ng/L identified 154 patients (43.5%) as low risk, with a sensitivity and a negative predictive value of 100%.
The authors concluded that a novel point-of-care troponin assay that can produce a result 15 minutes after blood sampling had comparable discrimination ability to an hs-cTnI assay for ruling out AMI after a single blood test. Use in the ED may facilitate earlier decision-making and could expedite the safe discharge of a large proportion of low-risk patients. Additional usefulness of this assay is likely to be found outside of the ED, such as in rural hospitals and general practices where there is limited rapid access to laboratory-based troponin assays. The study was published on October 17, 2018, in the journal JAMA Cardiology.
Related Links:
Christchurch Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines